Hot Movers: Unilife Corp (NASDAQ:UNIS), Synageva BioPharma (NASDAQ:GEVA), Idenix Pharmaceuticals (NASDAQ:IDIX), Intercept Pharmaceuticals (NASDAQ:ICPT)

Unilife Corporation (NASDAQ:UNIS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction drug reconstitution delivery systems auto-injectors wearable injectors ocular delivery systems and novel systems. Unilife Corp (NASDAQ:UNIS) shares after opening at $4.36 moved to $4.36 on last trade day and at the end of the day closed at $3.98. Company price to sales ratio in past twelve months was calculated as 50.44 and price to cash ratio as 95.02. Unilife Corp (NASDAQ:UNIS) showed a negative weekly performance of -23.31%.

Synageva BioPharma Corp. (NASDAQ:GEVA)‘s stock had its “fair value” rating restated by investment analysts at Janney Montgomery Scott in a note issued to investors on Tuesday,AnalystRatingsNetwork.com reports. They currently have a $107.00 price target on the stock, up from their previous price target of $52.00. Janney Montgomery Scott’s price target points to a potential upside of 5.56% from the company’s current price. Synageva BioPharma Corp (NASDAQ:GEVA) shares fell -4.64% in last trading session and ended the day on $75.47. GEVA return on equity ratio is recorded as -25.00% and its return on assets is -24.10%. Synageva BioPharma Corp (NASDAQ:GEVA) yearly performance is 37.42%.

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced that it intends to file an appeal to challenge the Oslo, Norway District Court’s (the “Court”) decision in a patent invalidity case concerning Idenix’s co-owned Norwegian patent NO 330 755 that covers certain 2′-methyl-2′-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus (HCV) and other flaviviridae infections. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares moved down -3.32% in last trading session and was closed at $5.82, while trading in range of $5.73-$6.23. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) year to date performance is -2.68%.

Intercept Pharmaceuticals (NASDAQ:ICPT), Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company’s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) weekly performance is -18.76%. On last trading day company shares ended up $317.58. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) distance from 50-day simple moving average is 12.97%. Analysts mean target price for the company is $557.86.